Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.
This presentation is significant because it provides an opportunity for the investment community to gain insights into Kairos Pharma's lead candidate, ENV-105, an antibody designed to target CD105, a protein identified as a key driver of resistance and disease relapse in response to standard cancer therapies. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard treatments across multiple cancer types. This approach addresses a critical challenge in oncology: the ability of tumors to evade therapies and recur.
For patients and the broader healthcare industry, drug resistance remains a major hurdle in improving cancer outcomes. Many patients initially respond to treatment but later experience relapse due to resistance mechanisms. Kairos Pharma's strategy of using structural biology to understand and attack these mechanisms could potentially lead to more durable responses and better survival rates. If successful, ENV-105 could become an important addition to the cancer treatment arsenal, offering hope for those with limited options.
The conference presentation also highlights Kairos Pharma's progress in the clinical development of ENV-105. As a clinical-stage company, moving candidates through trials is critical for bringing new therapies to market. The company's focus on CD105 is particularly noteworthy, as this target is implicated in resistance across various cancer types, suggesting a broad potential application.
Investors and industry analysts will be watching closely for any updates on trial progress and future development plans. The H.C. Wainwright conference is a well-known venue for biotech companies to showcase their pipelines and attract potential partners or investors. Kairos Pharma's participation underscores its commitment to advancing its innovative approach and communicating its value proposition to the financial community.
For more information about the company and its recent news, interested parties can visit the company's newsroom at https://ibn.fm/KAPA. The full press release regarding this announcement is available at https://ibn.fm/NrBQD.
